Quantum Genomics Initiates
its Pivotal Phase III FRESH Trial in Difficult-to-Treat and Resistant Hypertension

Quantum Genomics Initiates its Pivotal Phase III FRESH Trial in Difficult-to-Treat and Resistant Hypertension

Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC, OTCQX – QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat resistant hypertension and heart failure, today announced the initiation of its pivotal Phase III FRESH study (Firibastat in treatment-RESistant Hypertension) in difficult-to-treat1 and resistant2 hypertension. The trial is being conducted in partnership with Biolab Sanus Pharmaceuticals, as announced on December 9, 2019.

Read the press release

Leave a Reply

Your email address will not be published.